Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bexidem versus BCG in superficial papillary bladder cancer
ISRCTN35881130Phase 3Completed
- Sponsor
- IDM Pharma
- Start
- Jun 2004
- Modality
- Vaccines & Immunotherapeutics, Cell Therapies
01
Overview
Phase 3, randomised, open-label trial in bladder cancer comparing Bexidem with BCG (2 arms). Primary endpoints: Safety profile and Recurrence-free survival. Started Jun 2004; status: completed.
02
Drugs
Bexidembcg vaccine
03
Conditions
bladder cancer
Beyond the preview
Go deeper on ISRCTN35881130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN35881130.